Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

NCT02870231 · Completed

Last updated 2026-05-28

This clinical trial is testing the safety and effects of different doses of the drug NNC9204-0530 when taken with liraglutide in adults who are overweight or have obesity.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 187 people

Who can join Ages 18–55 · all sexes

Timeline Started 2016-08 · est. completion 2017-09

Where 2 sites · United States

What this study is testing ClinicalTrials.gov NCT02870231 ↗

Description as written by the study sponsor.

This trial is conducted in the United States of America. The aim of this trial is to investigate Safety, Tolerability, PK (the exposure of the trial drug in the body) and PD (the effect of the investigated drug on the body) for Multiple Doses of NNC9204-0530 in Combination with Liraglutide in Male and Female Subjects being Overweight or with Obesity

Treatments tested

NNC9204-0530 Drug

Once-daily subcutaneous (s.c., under the skin) administration.
liraglutide Drug

Once-daily subcutaneous (s.c., under the skin) administration.
placebo Drug

Once-daily subcutaneous (s.c., under the skin) administration

Main thing measured	Number of treatment emergent adverse events
Sponsor	Novo Nordisk A/S
Conditions studied	Metabolism and Nutrition Disorder, Obesity
GLP-1 drugs	liraglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02870231 ↗